AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03542344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single rising oral dose
Study NCT03707327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game Ready
Description: the participants remained for 20 minutes with intermittent compression therapy + cryotherapy
Study NCT03707327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice pack
Description: the participants remained for 20 minutes with cryotherapy with ice pack
Study NCT03789045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic thresholds and fat oxidation points relationship
Description: Investigators aim to determine exercise intensity at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables. Bland-altman will be used to determine levels of agreement.
Study NCT02432404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing
Study NCT02432404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing
Study NCT02060149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C/S plus minocycline.
Description: Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
Study NCT02060149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C/S plus minocycline.
Description: Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
Study NCT02060149 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: C/S plus minocycline.
Description: Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
Study NCT02060149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulization with pH 7.4 solution
Description: Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
Study NCT02060149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulization with pH 7.8 solution
Description: Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
Study NCT02060149 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: No nebulization
Description: No nebulization will be given to the patients.
Study NCT00329654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy with the Embar® light therapy or sham irradiation
Description: Phototherapy with the Embar® light therapy or sham irradiation is followed.
Study NCT02848183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02848183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Study NCT02848183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study NCT02848183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02848183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Study NCT04122092 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The level of plasma cfDNA CINs
Description: The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs
Study NCT00268996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-480848
Description: SB-480848 is available as enteric-coated, free-base micronized tablet
Study NCT00268996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SB-480848 matching placebo
Description: Placebo is available as enteric-coated, free-base micronized tablet
Study NCT01862562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Conventional technique
Study NCT01862562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: New minimum invasive technique
Study NCT00061698 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy Child Only
Description: Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief.
Study NCT00061698 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT plus Parent Training
Description: Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief. Parents learned skills that helped their child to apply the strategies they learned. Parents learned how to better communicate positive information that helped their child build a positive core belief. Parents learned how to use reinforcement to support healthy behavior.
Study NCT00331279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cinnamon Extract
Description: A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
Study NCT00331279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills in likeness of the cinnamon extract
Study NCT03627689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active air purifier in respiratory allergies/asthma
Description: Continuous use of air purifier to improve allergies and asthma control
Study NCT03627689 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham air purifier
Description: control arm
Study NCT04451395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (UNIMMAP composition)
Description: The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.~Other Name: UNICEF, Micronutrient tabs, pregnancy/PAC-1000
Study NCT02520102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim GZ402664
Description: Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous
Study NCT02504606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besylsartan
Description: Amlodipin besylate 6.944mg+Losartan K 100mg
Study NCT02504606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amosartan
Description: Amlodipin besylate 7.841mg+Losartan K 100mg
Study NCT00532064 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT04181502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pneumatic tourniquet
Description: a pneumatic tourniquet around 200 mmHg after venous chase of the lower limb, during 5 minutes then deflated. Repeated twice after general anaesthesia and prior to incision.
Study NCT04181502 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No inflation
Description: No inflation of the pneumatic tourniquet placed on the lower limb
Study NCT00532064 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01917136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-acetate
Description: For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
Study NCT01917136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluoro-2-deoxy-2-D-glucose
Description: For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
Study NCT01917136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
Study NCT01914900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin, 5 fluorouracil
Study NCT02659631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06671008
Description: Dose Escalation Phase - Part 1
Study NCT02659631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06671008
Description: Dose Expansion Phase - Part 2
Study NCT02550366 — intervention group
Intervention type: DRUG
Intervention: MRI Contrast
Description: MRI Contrast
Study NCT02211521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: 3ml of PRP
Study NCT02211521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: 3ml hyaluronic acid
Study NCT00871117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals'Kinrix®
Description: One dose as intramuscular injection at visit 1
Study NCT00871117 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals'Kinrix®
Description: One dose as intramuscular injection at visit 1
Study NCT00871117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Merck and Company's MMRII
Description: One dose as subcutaneous injection at visit 1
Study NCT00871117 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Merck and Company's MMRII
Description: One dose as subcutaneous injection at visit 1
Study NCT00871117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Merck and Company's Varivax
Description: One dose as subcutaneous injection at visit 1 or at visit 2
Study NCT00871117 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Merck and Company's Varivax
Description: One dose as subcutaneous injection at visit 1 or at visit 2
Study NCT03293433 — intervention group
Intervention type: OTHER
Intervention: Blood punction
Description: 1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of micro RNA.
Study NCT01218100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol and lisinopril (free combination)
Description: nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks
Study NCT01218100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebivolol monotherapy
Description: nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks
Study NCT01218100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril monotherapy
Description: lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
Study NCT01218100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
Study NCT02887053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT02178813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of minocycline
Description: Administration of minocycline with the following schedule:~* Day prior to procedure: 800mg p.o., 700mg p.o.~* Day of procedure: 600mg i.v., 500mg p.o.~* Day after procedure: 400mg p.o., 400mg p.o.
Study NCT03403231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
Study NCT03403231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
Study NCT03353636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: 150mg elemental magnesium
Study NCT03353636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: 150mg elemental magnesium
Study NCT03353636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour
Study NCT04108403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Inducing Massage
Description: A pain inducing massage (pain intensity = 50/100) will be applied for 60 seconds, 4 times.
Study NCT04108403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Inducing Massage
Description: A pain inducing massage (pain intensity = 50/100) will be applied for 60 seconds, 4 times.
Study NCT04108403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Free Massage
Description: A pain free massage (pain intensity = 0/100) will be applied for 60 seconds, 4 times.
Study NCT04108403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Expectation Instructional Set
Description: Participants will be instructed that the massage is effective for some people with neck pain.
Study NCT04108403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Expectation Instructional Set
Description: Participants will be instructed that the massage is effective for some people with neck pain.
Study NCT04108403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative Expectation Instructional Set
Description: Participants will be instructed that the massage is ineffective for some people with neck pain.
Study NCT02394613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX776
Description: Single intravenous injection
Study NCT03779789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Antidepressant classified under the category other antidepressants according to the ATC/DDD index \[ATC=Anatomical Therapeutic Chemical Classification System; DDD=Defined Daily Dose\]. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-20 mg/day).
Study NCT03779789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 50-200 mg/day).
Study NCT01071200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)
Description: One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
Study NCT01071200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-hFSH
Description: One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
Study NCT01146652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191 (REGN88)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT03779789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 10-20 mg/day).
Study NCT03779789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-10 mg/day).
Study NCT03779789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-40 mg/day).
Study NCT03779789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day).
Study NCT03779789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvoxamine
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 100-300 mg/day).
Study NCT02499601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CORolla™ TAA device
Study NCT01064466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETOPOSIDE - Usual
Description: Etoposide Injection
Study NCT02088619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Therapy (QOLT)
Study NCT02088619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart Healthy Education (HHE)
Study NCT04735211 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Pediatric Surgery with hospitalized
Study NCT01782976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: 2000 mg by vein twice weekly of each 28 day cycle.
Study NCT01782976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
Study NCT01782976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
Study NCT02071420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Workstation Intervention
Description: Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.
Study NCT02071420 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ergonomic Intervention
Description: Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
Study NCT02071420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ergonomic Intervention
Description: Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
Study NCT02071420 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Email Intervention
Description: Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).